Using Modern Imaging Technology

Learn More

With new, proprietary drug formulations

Learn More

To precisely treat late stage and metastatic cancer

Learn More

and to stimulate a natural, adaptive immune response.

Learn More

Intensity Therapeutics is creating a new, highly effective cancer treatment - in situ vaccination.

Learn More

About Intensity Therapeutics

The Management


Founder and CEO

Lewis H. Bender



Prior to founding Intensity Therapeutics, from January 2008 until 2012 Mr. Bender was the CEO of Interleukin Genetics, a personalized medicine company.  At Interleukin Mr. Bender successfully restructured the Company, increased sales eight fold, developed a new genetic-based testing platform and partnered with a large insurance provider to initiate studies leading to reimbursement of the Company’s lead product.  Prior to joining Interleukin Genetics, Mr. Bender held numerous positions at Emisphere Technologies, Inc., a drug delivery company specializing in the oral delivery of poorly absorbed molecules. While at Emisphere from 1993 to December of 2007 Mr. Bender held positions as; Interim President & CEO, Chief Technology Officer, Senior Vice President of Business Development, and Vice President of Manufacturing and Process Development. During his career Mr. Bender has partnered with several major pharmaceutical and biotech companies using structures such as joint ventures, licensing and research collaboration agreements.  Mr. Bender has over 22 years of biotech and pharmaceutical experience having led teams taking products from discovery to Phase III for compounds using novel drug delivery techniques.  In addition, Mr. Bender has been successful in raising (or helping to raise) capital with institutional investors using several vehicles such as registered direct placements, PIPES, S-3 & S-1 filings, and convertible debt.  Most recently for Intensity Therapeutics he has raised approximately $2,200,000 in capital with investors.

Mr. Bender has both a S.B. and S.M. in Chemical Engineering from MIT, an MBA from UPENN’s Wharton School, and an MA in International studies also from UPENN. He spent several years living in Switzerland and speaks French, German and Swiss-German dialect.


Vice President and Chief Medical Officer
Ian B. Walters, MD


Dr. Walters has over 15 years of oncology/immunology drug development experience. Prior to joining Intensity Therapeutics Dr. Walters spent seven years at Bristol-Myers Squibb (BMS), where he led clinical research and matrix development teams. During his tenure there he contributed to the development of multiple immuno-oncology products (Yervoy® and Nivolimumab (anti-PD-1)), as well as the licensing and partnering strategy for other immuno-oncologic agents. Dr. Walters has worked in multiple biotech companies on corporate development, translational medicine, clinical development and medical affairs including Millennium Pharmaceuticals. Dr. Walters also has been a consultant to biotech, pharma and investment companies specializing in the evaluation, prioritization, and development of innovative technologies in the treatment of severe diseases. Before entering the private sector, Dr. Walters was a lead investigator at the Rockefeller University and initiated cutting edge immunology research to understand the mechanism of action of several compounds. Dr. Walters received his MD from the Albert Einstein College of Medicine and an MBA from the Wharton School of The University of Pennsylvania.


Vice President, Project Management

Caroline Hill, Ph.D.



Prior to joining Intensity Therapeutics, Caroline Hill spent 13 years at BMS in R&D operations, with her most current role as Head Regional R&D operations and Schedule management, having responsibility across the portfolio covering Discovery to life cycle management. Prior to this role, Caroline was responsible for the management of the Specialty portfolio including CV, IMS, Virology, Fibrotic Disease and Genetically Defined Diseases and has been involved with managing multiple licensing, partnering and acquisition opportunities.


Prior to joining BMS, Caroline spent 8 years at Vion Pharmaceuticals, starting as a research scientist in Microbiology and ending her tenure as the Director of Quality Control/ Analytical and Bio-Analytical Development and Manufacturing where she was responsible for all pre-clinical and clinical analytical development for biologics and small molecules as well as analysis of clinical samples and all operational logistics to support clinical PK/PD.


Prior to her employment with Vion, Caroline spent 4 years at Yale in the department of Therapeutic Radiology and Genetics investigating the role of DNA polymerase in base excision repair (BER) and the role of BER in carcinogenesis.


Caroline received her BA in Biochemistry from Clark University and her PhD in Biochemistry and Molecular Biology from the University of Massachusetts Medical School and completed her post-doctoral work at Yale University. While at Yale Caroline helped to establish the CT chapter for the Association for Women in Science (AWIS) and served as President from 2001-2003.



John Wesolowski, CPA, MBA


Prior to joining Intensity Therapeutics, from 1998 to 2016 John Wesolowski was Director of Costing in the Yale University Controller’s office. In that role John conducted financial reporting, property tax management, was responsible for calculations of overhead and benefit rates, and was involved in numerous special projects related to accounting process and controls. Also at Yale, he was involved in financial reporting and the accounting matters related to clinical trials and other organized research. Prior to joining Yale John was the Vice President and Controller for Automatic Fastener Corporation in Branford, CT from 1988 to 1998. In this role, John oversaw all accounting, purchasing and human resource functions. John also has 5 years of experience in public accounting and auditing from working at KMG Main Hurdman, now KPMG.


John Wesolowski received a Bachelor of Science in Finance from The Pennsylvania State University (Penn State at University Park) and an M.B.A from the University of Connecticut in Management Science. He is a Certified Public Account since 1983.


Contact Us

Intensity Therapeutics, Inc.
61 Wilton Road, 3rd Floor
Westport, CT 06880

Tel. (203) 221-7377
Fax (203) 664-1051


Click here for career inquiries

Who we are

Intensity Therapeutics is a clinical development stage company.  We are seeking partnerships/investors interested in advancing the company’s anti-cancer platform technology and lead product INT230-6.


Click here for inquiries